Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Alabama bill targets andro, DHEA

This article was originally published in The Tan Sheet

Executive Summary

The sale of dietary supplements containing androstanedione, dehydroepiandrosterone or ephedrine alkaloids to consumers under 18 years of age would be prohibited under a bill recently introduced in the Alabama state legislature. The proposal requires that sellers obtain valid identification from purchasers, and makes violation of the law a Class A misdemeanor. HB 356, sponsored by Rep. Tommy Sherer (D) and House Majority leader Ken Guin (D), was referred to the Health Committee March 15. In other DHEA-related legislative activity, an Oregon state bill would bar school employees from endorsing use of performance-enhancing supplements by students, while a federal bill by Sen. Charles Grassley, R-Iowa, would list DHEA as an anabolic steroid under the Controlled Substances Act (1"The Tan Sheet" March 19, 2007, In Brief and 2"The Tan Sheet" March 12, 2007, In Brief)...

You may also be interested in...

Oregon DHEA bill

School employees would be prohibited from knowingly endorsing or suggesting the ingestion of any performance-enhancing supplement to students under a bill recently introduced by Oregon Senate President Peter Courtney, D-Salem. The legislation, SB 517, also contains provisions that would partner the Department of Education with voluntary organizations to develop educational programs for students to prevent the use of steroids and performance-enhancing supplements. The Act is declared an "emergency" measure and would punish violators with three months imprisonment or $500 or both. The bill passed the Senate Education and General Government subcommittee on March 13, according to Courtney's staff. Sen. Courtney introduced a similar bill in 2005. It passed the Senate but was defeated in the House...

BrightGene Bets On Remdesivir Amid Patent Questions

Despite many uncertainties, Suzhou-based BrightGene sees a bet on generic remdesivir worthy of a $700,000 investment.

QUOTED. 17 February 2020. Ralph Ives.

The Chinese government's plan to reduce tariffs it imposed on a slew of US exports is expected to have minimal impact on the overall medtech industry. See what Ralph Ives, AdvaMed's executive VP for global strategy, said about it here.   





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts